Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin
Comparison in people · 2009
- What was studied
- Clinical population; enrollment and allocation not verified
- What the source reports
- This publication compared Noopept and piracetam in patients with mild cognitive impairment of vascular or traumatic origin. The indexed citation gives no numerical comparison. Its title and authors overlap with the 2008 publication.
Study data at a glance
- Participants or experimental model
- Clinical population; enrollment and allocation not verified
- Reported results
- This publication compared Noopept and piracetam in patients with mild cognitive impairment of vascular or traumatic origin. The indexed citation gives no numerical comparison. Its title and authors overlap with the 2008 publication.
Study limitations and source details
Study limitations
- No effect size, participant count or safety conclusion is inferred from the title.
- The 2008/2009 comparison and related EEG report may overlap; not counted as independent replication.
Related publications may describe some of the same participants or experiments.
Source details
Indexed citation
Indexed citation checked; complete article not recovered. Study type is based on the database record and abstract, where available.
Metadata only
Sources checked
Citation
Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin Neuroscience and behavioral physiology
Study source ↗ · DOI 10.1007/s11055-009-9128-4 · Bibliography entry · Link to this summary
Related compounds
Noopept
Omberacetam (GVS-111), a synthetic derivative of the Pro–Gly dipeptide. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. Studies examined cognition and the metabolite cycloprolylglycine.
Piracetam
A synthetic compound in the racetam family, also known by the brand Nootropil. It appears in neurological research and historical fatigue-related combination studies.